Cyanotech Corporation

CYAN

US2324373016

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 01:28:52 02/07/2024 am IST			5-day change	1st Jan Change
0.326 ^USD	0.00%		+23.02%	-63.37%

28/06	Transcript : Cyanotech Corporation, Q4 2024 Earnings Call, Jun 27, 2024
26/06	Cyanotech Corporation Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Cyanotech Corporation Reports Earnings Results for the Full Year Ended March 31, 2024

June 26, 2024 at 05:30 pm IST

Cyanotech Corporation reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was USD 23.07 million compared to USD 23.18 million a year ago. Sales was USD 23.07 million compared to USD 23.18 million a year ago.

Net loss was USD 5.27 million compared to USD 3.44 million a year ago. Net loss was USD 5.27 million compared to USD 3.44 million a year ago. Basic loss per share from continuing operations was USD 0.81 compared to USD 0.55 a year ago.

Basic loss per share from continuing operations was USD 0.81 compared to USD 0.55 a year ago. Diluted loss per share from continuing operations was USD 0.81 compared to USD 0.55 a year ago. Diluted loss per share from continuing operations was USD 0.81 compared to USD 0.55 a year ago.

Latest news about Cyanotech Corporation

Transcript : Cyanotech Corporation, Q4 2024 Earnings Call, Jun 27, 2024	28/06
Cyanotech Corporation Reports Earnings Results for the Full Year Ended March 31, 2024	26/06	CI
Cyanotech Corporation(NasdaqCM:CYAN) dropped from S&P TMI Index	22/02	CI
Cyanotech Corporation(NasdaqCM:CYAN) dropped from NASDAQ Composite Index	19/02	CI
Transcript : Cyanotech Corporation, Q3 2024 Earnings Call, Feb 09, 2024	10/02
Earnings Flash (CYAN) CYANOTECH CORPORATION Posts Q3 Revenue $5.6M	08/02	MT
Cyanotech Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02	CI
Cyanotech Insider Bought Shares Worth $400,000, According to a Recent SEC Filing	20/12	MT
Cyanotech Corporation announced that it has received $0.4 million in funding from The Michael Arlen Davis Revocable Trust	15/12	CI
Cyanotech Corporation Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
Cyanotech Corporation Enters into A Second Amendment to the Amended and Restated Promissory Note with Skywords Family Foundation, Inc	18/23/18	CI
Transcript : Cyanotech Corporation, Q1 2024 Earnings Call, Aug 14, 2023	15/23/15
Earnings Flash (CYAN) CYANOTECH CORPORATION Posts Q1 Revenue $5.1M	11/23/11	MT
Cyanotech Corporation Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Cyanotech Corporation Appoints Collette Kakuk as Chief Strategic and Commercial Officer	01/23/01	CI
Cyanotech Corporation and Skywords Family Foundation, Inc. Executes Letter of Intent to Commence Drafting and Negotiating A Definitive Second Amendment to the Amended and Restated Promissory Note	06/23/06	CI
Earnings Flash (CYAN) CYANOTECH CORPORATION Reports Q4 Revenue $5.4M	28/23/28	MT
Cyanotech Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	28/23/28	CI
Cyanotech Corporation Auditor Raises 'Going Concern' Doubt	27/23/27	CI
Earnings Flash (CYAN) CYANOTECH CORPORATION Reports Q3 Revenue $5.9M	09/23/09	MT
Cyanotech Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	09/23/09	CI
Top Premarket Decliners	17/23/17	MT
Cyanotech Corporation Enters into First Amendment to Amended and Restated Promissory Note with Skywords Family Foundation, Inc	20/22/20	CI
Cyanotech Corporation Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/22/09	CI
Earnings Flash (CYAN) CYANOTECH CORPORATION Posts Q1 Revenue $6.7M	10/22/10	MT

Chart Cyanotech Corporation

Duration

Period

More charts

Company Profile

Cyanotech Corporation is an agricultural company. It is engaged in the production of natural products derived from microalgae grown in complex and intricate agricultural systems on the Kona coast of Hawaii. It cultivates, on a large-scale basis, two microalgal species from which its two major product lines, natural astaxanthin products and spirulina products, are derived. Its products include BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. BioAstin Hawaiian Astaxanthin is a dietary antioxidant shown to support and maintain the bodyâs natural inflammatory response, to enhance skin, and to support eye, joint and immune health. BioAstin Hawaiian Astaxanthin has expanding applications as a human dietary supplement and dietary ingredient. Hawaiian Spirulina Pacifica is a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids. Its products are sold as consumer-packaged goods.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CYANOTECH CORPORATION	-63.37%	22.65L
ELI LILLY AND COMPANY	+56.86%	82TCr
NOVO NORDISK A/S	+42.03%	64TCr
JOHNSON & JOHNSON	-6.57%	35TCr
MERCK & CO., INC.	+17.32%	32TCr
ABBVIE INC.	+9.94%	30TCr
ASTRAZENECA PLC	+15.32%	24TCr
ROCHE HOLDING AG	+1.76%	22TCr
NOVARTIS AG	+13.57%	22TCr
AMGEN INC.	+7.98%	17TCr